Sai Life Sciences announced a key leadership transition effective 1 April 2026. Dr. John Pavey, currently Head of Global PR&D, has been appointed as a Senior Management Personnel (SMP). He succeeds Dr. Dean David Edney, Head – Global PR&D, who is retiring on 31 March 2026. Dr. Pavey brings over two decades of global experience in chemical development from major pharmaceutical firms.
Leadership Transition in R&D
Sai Life Sciences Limited has confirmed a strategic appointment within its senior management team, effective starting 1 April 2026. Dr. John Pavey, who currently serves as the Head – Global PR&D, will assume the role of Senior Management Personnel (SMP) for the Company.
Succession Planning
This transition is necessitated by the retirement of the incumbent, Dr. Dean David Edney, Head – Global PR&D. Dr. Edney will officially retire from his position effective at the close of business hours on 31 March 2026.
Profile of Incoming SMP
Dr. Pavey brings extensive international expertise to the SMP role, boasting over two decades of global experience in CMC and chemical development. His background includes senior leadership positions at prominent companies such as Johnson & Johnson, UCB, and AstraZeneca. His specialized knowledge covers the entire API development lifecycle, regulatory approvals, and commercial supply.
Academically, Dr. Pavey holds a BA (Hons) in Chemistry from the University of Oxford and a PhD in Organic Chemistry from the University of Liverpool, followed by postdoctoral research at the University of Cambridge.
Disclosure Summary
In alignment with required disclosures, the document confirms that the incoming SMP, Dr. John Pavey, has no reportable relationships with any existing directors of the Company.
Source: BSE
